Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
18 December 2018Website:
http://www.aptorumgroup.comNext earnings report:
20 December 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 46 min agoDividend
Analysts recommendations
Institutional Ownership
APM Latest News
Clinical-stage biopharmaceutical firm Aptorum (NASDAQ: APM ) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what's helping APM stock rocket higher.
Aptorum (NASDAQ: APM ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group. This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete.
Aptorum (NASDAQ: APM ) stock is falling on Monday after the company received a delisting notice from the Nasdaq Stock Market LLC. The reason given for the delisting notice is Aptorum failing to maintain proper equity to remain on The Nasdaq Global Market.
Aptorum (NASDAQ: APM ) stock is climbing higher on Wednesday despite a lack of news from the clinical-stage biopharmaceutical company. However, trading of APM stock is taking off today with more than 1 million shares on the move.
Aptorum Group saw its market capitalization double following a busy week where the biopharmaceutical firm released its latest results and announced a merger plan. Shares of the Nasdaq-listed company were up over 109% by midday Wednesday at US$5.85.
What type of business is Aptorum Group Limited?
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
What sector is Aptorum Group Limited in?
Aptorum Group Limited is in the Healthcare sector
What industry is Aptorum Group Limited in?
Aptorum Group Limited is in the Biotechnology industry
What country is Aptorum Group Limited from?
Aptorum Group Limited is headquartered in United Kingdom
When did Aptorum Group Limited go public?
Aptorum Group Limited initial public offering (IPO) was on 18 December 2018
What is Aptorum Group Limited website?
https://www.aptorumgroup.com
Is Aptorum Group Limited in the S&P 500?
No, Aptorum Group Limited is not included in the S&P 500 index
Is Aptorum Group Limited in the NASDAQ 100?
No, Aptorum Group Limited is not included in the NASDAQ 100 index
Is Aptorum Group Limited in the Dow Jones?
No, Aptorum Group Limited is not included in the Dow Jones index
When does Aptorum Group Limited report earnings?
The next expected earnings date for Aptorum Group Limited is 20 December 2024